Pembrolizumab: Immune check point related myocarditis.

A 54-year-old man developed immune checkpoint-related myocarditis (ICIM) while being treated with pembrolizumab for acute myeloid leukemia. Three days after receiving pembrolizumab, he experienced ventricular tachycardia, severe chest pain, and shortness of breath. Diagnostic tests confirmed the presence of ICIM, and his treatment with pembrolizumab was discontinued. He was started on methylprednisolone and colchicine, and his symptoms resolved within three days. After eight weeks, his ICIM symptoms were completely resolved. [Extracted from the article]